Med-X, Inc. Signs Letter of Intent to Acquire Pacific Northwestern Custom Bed Bug, Inc. to Continue Expansion of its Nature-Cide Service Division

LOS ANGELES, May 29, 2019 /PRNewswire/ -- Med-X, Inc. announced today that it has signed a non-binding Letter of Intent to acquire Custom Bedbug, Inc, a Pacific Northwest based company with over 20 years of experience in the pest control industry, and over 10 years specifically dedicated to bed bugs.  Custom Bedbug uses the most innovative, environmentally-friendly treatments for their broad base of commercial and residential customers throughout Idaho, Oregon, Utah and Washington.

Following the acquisition, Custom Bedbug will continue to independently run and grow its business and service their loyal customers, but do so under Med-X's Nature-Cide service division.  Nature-Cide is Med-X's brand of all-natural line of green solutions for commercial pest-control applicators and runs its own service division in Southern California.  Nature-Cide products are currently being distributed and applied nationwide for residential and commercial applications within a wide variety of industries including hospitality, turf-care, food service, public schools, hospitals, transportation and agriculture.

Med-X, President, Matthew Mills, stated that "Custom Bedbug has the same vision and approach as Nature-Cide in regard to eco-friendly safe and effective pest control.  We see this as a great match to support and assist with the growth of Custom Bedbug's core business model while also incorporating Nature-Cide strategy and products into their service throughout the Pacific Northwest."  This acquisition follows-up on Med-X's announcement of Acquiring Akamai Pest Solutions, which offers natural termite solutions in the Hawaiian Islands.

Hans Madson, co-owner of Custom Bedbug, explained that the decision to merge Custom Bedbug into the Nature-Cide division was easy.  "We will now be aligned with a growing company with exciting products that, like us, is dedicated to an environmentally conscious approach to pest control.  We look forward to consummating this partnership as it will allow us to expand our territory footprint, offerings to our customers and create greater opportunity for everyone working for Custom Bedbug, Inc."

The closing of the acquisition is subject to several conditions, including without limitation, satisfactory completion of due diligence investigation and execution of a definitive Purchase Agreement.  Accordingly, there is no assurance that the Custom Bed Bug, Inc. transaction will be consummated. 

ABOUT NATURE-CIDE: Nature-Cide, provides our commercial and residential customers with all-natural, green, environmentally friendly and effective products via different applications for the control of insects while repelling rodents, reptiles and various birds.  The Nature-Cide product line was first implemented via California licensed IPM (integrated pest management) service company "Nature-Cide Service."  The Nature-Cide products are now positioned in professional pest control, hospitality, janitorial and agriculture.  For more information, please visit https://nature-cide.com or email [email protected].

ABOUT MED-X:  Med-X, Inc. is a revenue generating "Green Scene" company with multiple divisions.  Med-X's core lines involve all-natural products including the Nature-Cide division described above.  Med-X also has the Thermal-Aid division, which consists of patented and clinically proven Thermal-Aid hot and cold pain management modality products, which also include the Thermal-Aid Zoo and the Thermal-Aid Headache Relief System.  Both lines are distributed nationally through large scale distribution partners.  Med-X also operates a media division which owns and operates the MJT Network which includes The Marijuana Times.  Med-X, Inc. also recently launched a new division named Malibu Brands which initially released the Pacific Pain Relief Cream, which is currently being offered in an IndieGoGo crowdfund campaign which discounts the products for consumers prior to management offering the first of many planned products to retail and distribution.  

No Offer or Solicitation Securities

This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

Med-X, Inc. Cautionary Statement Regarding Forward-Looking Statements

There may be statements in this communication that are, or could be, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and, therefore, subject to risks and uncertainties, including, but not limited to, statements regarding Med-X, Inc. or the combined company's future financial position, sales, costs, earnings, cash flows, other measures of results of operations, capital expenditures or debt levels are forward-looking statements. Words such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "should," "forecast," "project" or "plan" or terms of similar meaning are also generally intended to identify forward-looking statements. Med-X, Inc. cautions that these statements are subject to numerous important risks, uncertainties, assumptions and other factors, some of which are beyond Med-X, Inc.'s control, that could cause Med-X, Inc. or the combined company's actual results to differ materially from those expressed or implied by such forward-looking statements. To learn more about the risk factors, please review Med-X, Inc.'s Regulation A+ offering circular. Contact Information: Med-X, Inc. 8236 Remmet Ave, Canoga Park, California 91304, (818) 349-2870.

For more information or media regarding Med-X, Inc. and its divisions, please visit www.medx-rx.com and/or email [email protected] or call 818-349-2870.

SOURCE Med-X, Inc.

Related Links

http://medx-rx.com